The life sciences and therapeutic landscapes are incredibly dynamic and rapidly changing. What was relevant 5 years ago is more than likely outdated and mute today. The real challenge is staying ahead of the curve to foresee what will be relevant 5 years from now with these continuously growing markets. Kineticos Life Sciences white papers provide a unique and different primer on various therapeutic areas, indications, and technologies. We not only offer our position on the associated epidemiology and history, market trends, addressable patient populations, technologies, assets, IP, and relevant competitors, we will take the next step and provide an important view of the future discussing the challenges and possibilities for each of these markets.

Beyond CAR-T: Other Engineered Immune Cells

Kineticos is excited to partner with a few of the pioneers in cell therapy to bring you: Beyond CAR-T: Other Engineered Immune Cells. Our panelists come from Inceptor Bio, a novel Cell and Gene Therapy company. Mike Nicholson, CSO at Inceptor Bio, Chris Heery, CMO at Arcellx and SAB member at Inceptor Bio, and Mark Gilbert, Formerly of Juno Therapeutics and SAB member at Inceptor Bio discuss CAR-T for solid tumors, allogeneic CAR-T, CAR-NK and CAR-Macrophage, as well as manufacturing cell therapies.

Click here to read the full article

Ongoing Challenges and Outlook for Rare Disease Drug Development

There are an estimated 7,000 rare diseases that affect 25 to 30 million people in the United States, more than half of whom are children, with treatments are available approximately 5% of these conditions. Many of these diseases are life-threatening, genetic in origin, and only recently new treatments are bringing the prospect of a better life to some patients. This article dives deep into the current situation and future outlook of the world of rare diseases, including scientific innovation requirements, regulatory flexibility and pricing negotiations, and the growth and success of rare disease drug development and commercial launches.

Click here to read the full article

A Primer on Gene Editing

Gene editing has recently emerged as a revolutionary scientific tool which may be utilized for therapeutic applications such as curing disease, as well as for the creation of animal models for disease research and therapeutics development, agricultural development, genome wide screening, and basic research. In the past two decades, great advances have been made in genome editing technologies through the use of systems, comprised of nucleases combined with target sequence specific DNA binding domains, allowing for direct manipulation of virtually any gene.

Click here to read the full article

Cell and Gene Therapies: The Path to Commercialization

As the pharmaceutical industry continues to explore new therapeutic avenues and build on scientific advances in medicine and the biosciences, regenerative medicine presents the potential to address unmet medical needs with novel transformative treatments that are specifically designed to alter disease states by regenerating, replacing, or supplementing natural physiological mechanisms and restoring them to a healthier state.

Click here to read the full article

Are we Manufacturing the right T-Cells And a Look at the Future of Oncology Precision Medicine

The final part of the discussion between Kineticos’ Operating Executive, Steve Buckanavage and Precision Biosciences’ CMO, Christopher Heery M.D., covers the advancement of T-cell generation and what the future holds for Oncology research. Click the link below to view the whole article.

Click here to read the full article

Is Precision Medicine in Oncology Narrowing Patient Population Too Much?

Kineticos’ Operating Executive Steve Buckanavage, continues his discussion with Christopher Heery, M.D., CMO at Precision Biosciences as they tackle the difficulties that Precision Medicine can bring to Oncology studies. To read the whole article, click the link below.

Click here to read the full article

Can We Create Companion Diagnostics In Oncology With What We Know About Biomarkers?

As we continue our discussion between Steve Buckanavage, Kineticos’ Operating Executive and Christopher Heery, M.D., CMO at Precision Biosciences, we discuss Biomarkers and their impact in diagnosing individual patients versus segmenting patient populations. To read the whole article, click the link below.

Click here to read the full article

Are Checkpoint Inhibitors Impacting How We Cure Disease?

We’re discussing Precision Medicine and it’s impact on various segments of the life sciences. Steve Buckanavage, Kineticos Operating Executive, engages with Precision Biosciences’ CMO, Christopher Heery, to discuss how Precision Medicine is playing in Oncology. See below to read Steve and Chris’ discussion on how checkpoint inhibitors are impacting the potential cures for many cancers.

Click here to read the full article

Visualizing the Future of Contract Development and Manufacturing for Cell and Gene Therapies

“Next-generation medicines, such as cell and gene therapy, are providing significant opportunities for growth in the innovator, CRO, and CDMO marketplaces. However, there are numerous challenges associated with these therapies that create measurable risk.”

Click here to read the full article

A Primer on CAR-T Cell Therapy

“In the world of cancer detection, diagnosis, and treatment, there is a continuous stream of new ideas and inventions that alter our understanding of standards of care and patient outcomes… Although there are many treatment options available, few have received the same level of public attention as chimeric antigen receptor T cell (CAR-T) therapy. CAR-T therapy involves the reprogramming of the hosts’ (or patient’s) own T cells.”

Click here to read the full article

A Primer on Immuno-Oncology: Part 2 – Targeted Redirection of T Cells

In the second part of this Immuno-Oncology Primer, we will provide an overview of immune checkpoint inhibitors, bispecific T cell engagers, and CAR T cells.

“Immune checkpoint inhibitors, BiTEs, and CAR-T cells all utilize T cells in their fight against cancer, but in differing ways.  Whereas immune checkpoint inhibitors amplify antigen-specific T cell response, BiTEs provide assistance in increasing T cell activity, and CAR-T cell therapy augments the capabilities of T cells.”

Click here to read the full article.

A Primer on Immuno-Oncology: Part 1

In the first part of the Immuno-Oncology Primer, we will provide an overview of anti-cancer vaccines and cytokines before delving into a discussion of immune checkpoint inhibitors.

“These successes have refocused attention back on to immunotherapeutic approaches for treating cancer; specifically, the discovery and clinical successes of immune checkpoint inhibitors have revolutionized cancer immunotherapy, and the cancer immunotherapy market is forecasted to have sales of >$93B in 2023, the majority of which may be attributed to immune checkpoint inhibitors…”

Click here to read the full article.

Primary Research: An Effective Risk Mitigation Tool

The life science industry relies heavily on market research. The evolving nature of the industry, along with the extremely high financial stakes, stresses the need for market data. Whether it is an emerging biotech trying to determine their molecule’s lead indication, or a diagnostic company exploring a new geographic market, there is no substitute for having a comprehensive understanding of market dynamics supported by an in-depth, data-supported analysis.

“One of the most important reasons for companies to consider outsourcing primary research is for the same reason these companies want to conduct primary research in the first place; it is a unique problem associated with performing primary research.”

Click here to read the full article.

A Primer on Regenerative Medicine

The two most groundbreaking and fastest-growing areas of regenerative medicine are cell and gene therapies, with small molecules and biologics, tissue-engineered biomaterials and scaffolds, and implantable devices representing the majority of other sub-areas. Cell therapies utilize fully-differentiated cells and/or progenitor cells to repair diseased tissue and overall body systems, either through an autologous or allogenic pathway. Moreover, the immune properties of these cells can be used as an immunological treatment against pathogens and cancer.

“The relevance of these therapies is illustrated by the fact that, according to a study conducted by BIS Research in 2018, cell therapies have had the fastest compound annual growth rate out of any other regenerative treatment methods.”

Click here to read the full Primer.

Subscribe to the Kineticos Research Institute to receive weekly emails containing insightful content.